Supernus Pharmaceuticals (SUPN) Income from Non-Controlling Interests (2022 - 2023)
Supernus Pharmaceuticals' (SUPN) quarterly Income from Non-Controlling Interests came in at $554000.0 in Q2 2023, up 138.29% year-on-year from $232493.6 in Q2 2022, and down 37.12% on a QoQ basis from $881000.0 in Q1 2023.
Supernus Pharmaceuticals (SUPN) Income from Non-Controlling Interests (2022 - 2023) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 2 years of Income from Non-Controlling Interests data on file, last reported at $554000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.85 Bn | 32.11 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.48 Bn | 30.54 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.33 Bn | 18.53 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.43 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | - |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.35 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 554,000.00 |
| Mar 31, 2023 | 881,000.00 |
| Jun 30, 2022 | -1.45 Mn |
| Mar 31, 2022 | -2.31 Mn |